Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study

Cancer

Volumn 97, Issue 1, 2003, Pages 105-113

  Madžo, Jozef ^a   Zuna, Jan ^a   Mužíková, Kateřina ^a   Kalinová, Markéta ^a   Krejčí, Ondřej ^a   Hrušák, Ondřej ^a   Otová, Berta ^a   Starý, Jan ^a   Trka, Jan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Childhood leukemia; Minimal residual disease; Prognosis; Real time quantitative polymerase chain reaction; TEL AML1

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ANALYTIC METHOD; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CELL ASSAY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 21; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DISEASE-FREE SURVIVAL; DNA PRIMERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 0037214886     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11043     Document Type: Article

References (30)

1. Rubnitz JE, Pui CH, Downing JR. The role of TEL fusion genes in pediatric leukemias. Leukemia. 1999;13:6-13.
2. Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995;9:1985-1989.
3. Zuna J, Hrusak O, Kalinova M, Muzikova K, Stary J, Trka J. TEL/AML1 positivity in childhood ALL: Average or better prognosis? Czech Paediatric Haematology Working Group. Leukemia. 1999;13:22-24.
4. Trka J, Zuna J, Hrusak O, et al. Impact of TEL/AML1-positive patients on age distribution of childhood acute lymphoblastic leukemia in Czech Republic. Pediatric Hematology Working Group in Czech Republic. Leukemia. 1998;12:996-997.
5. Ford AM, Bennett CA, Price CM, Bruin MC, Van Wering ER, Greaves M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci USA. 1998; 95:4584-4588.
6. Loh ML, Silverman LB, Young ML, et al. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood. 1998;92:4792-4797.
7. Rubnitz JE, Behm FG, Wichlan D, et al. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. Leukemia. 1999;13:19-21.
8. Zuna J, Hrusak O, Kalinova M, Muzikova K, Stary J, Trka J. Significantly lower relapse rate for TEL/AML1-positive ALL. Leukemia. 1999;13:1633.
9. Harbott J, Viehmann S, Borkhardt A, Henze G, Lampert F. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood. 1997;90:4933-4937.
10. Seeger K, Adams HP, Buchwald D, et al. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Munster Study Group. Blood. 1998;91:1716-1722.
11. Biondi A, Valsecchi MG, Seriu T, et al. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia. 2000;14:1939-1943.
12. Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339:591-598.
13. Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998;351:550-554.
14. Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood. 2000;95:790-794.
15. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731-1738.
16. Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood. 2002;100:52-58.
17. Eckert C, Biondi A, Seeger K, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet. 2001;358:1239-1241.
18. Steward CG, Goulden NJ, Katz F, et al. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood. 1994;83:1355-1362.
19. Szczepanski T, Langerak AW, Wolvers-Tettero IL, et al. Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: Implications for selection of PCR targets for detection of minimal residual disease. Leukemia. 1998;12:1081-1088.
20. Ballerini P, Landman Parker J, Laurendeau I, et al. Quantitative analysis of TEL/AML1 fusion transcripts by real-time RT-PCR assay in childhood acute lymphoblastic leukemia. Leukemia. 2000;14:1526-1528.
21. Bolufer P, Barragan E, Verdeguer A, et al. Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes. Haematologica. 2002;87:23-32.
22. Drunat S, Olivi M, Brunie G, et al. Quantification of TEL-AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia. Br J Haematol. 2001;114:281-289.
23. Pallisgaard N, Clausen N, Schroder H, Hokland P. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12; 21) TEL-AML1 fusion transcript. Genes Chromosomes Cancer. 1999;26:355-365.
24. Seeger K, Kreuzer KA, Lass U, et al. Molecular quantification of response to therapy and remission status in TEL-AML1-positive childhood ALL by real-time reverse transcription polymerase chain reaction. Cancer Res. 2001;61:2517-2522.
25. Hrusak O, Trka J, Zuna J, Houskova J, Bartunkova J, Stary J. Aberrant expression of KOR-SA3544 antigen in childhood acute lymphoblastic leukemia predicts TEL-AML1 negativity. The Pediatric Hematology Working Group in the Czech Republic. Leukemia. 1998;12:1064-1070.
26. Otova B, Francova K, Franek F, et al. 9-[2-(phosphonomethoxy)ethyl]-2,6-diaminopurine (PMEDAP) - A potential drug against hematological malignancies - Induces apoptosis. Anticancer Res. 1999;19:3173-3182.
27. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
28. Zuna J, Hrusak O, Kalinova M, et al. [Monitoring minimal residual disease in pediatric patients with acute lymphoblastic leukemia.] Vnitr Lek. 2000;46:465-469.
29. de Haas V, Breunis WB, Dee R, et al. The TEL-AML1 real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia. Br J Haematol. 2002;116:87-93.
30. Krejci O, Otova B, Madzo J, et al. Asparagine synthetase gene and TEL/AML1 gene: Expression kinetics after L-asparaginase administration in TEL/AML1-positive cells. Blood. 2001;98:1330.